Trident Lifeline
BSE: TLL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Trident Lifeline's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Trident Lifeline Limited is a pharmaceutical company based in Surat that focuses on the marketing and distribution of a diverse range of pharmaceutical formulations. The company operates as a merchant exporter and domestic supplier, providing products across therapeutic segments such as anti-bacterial, anti-fungal, and cardiovascular drugs.
Business Model
The company employs a lean asset-light contract manufacturing model, outsourcing production while focusing on supply chain management and distribution. It generates revenue through the sale of pharmaceutical products in both domestic Indian markets and international regions including Africa, South East Asia, and Latin America.
- Listing Platform:BSE SME
- Listing Year:2022
Management Commentary
Management is prioritising the expansion of the company's global footprint through strategic product registrations and the strengthening of its distribution network.
Growth Outlook
Growth is expected to be driven by the continued scaling of distribution capabilities and the acquisition of new international product registrations. The company aims to leverage its lean operating structure to penetrate further into emerging pharmaceutical markets.
Key Risks
- Regulatory Risk. The company is subject to stringent pharmaceutical regulations and quality standards in both domestic and international markets, which could impact product approvals.
- Dependency on Contract Manufacturers. As an asset-light entity, the company relies on third-party manufacturers, making it vulnerable to supply chain disruptions or quality control issues at partner facilities.
- Currency Fluctuation. Significant exposure to international markets in Africa, South East Asia, and Latin America exposes the company to risks associated with foreign exchange volatility.
- Competitive Market. The pharmaceutical distribution sector is highly fragmented and competitive, which may exert pressure on profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Trident Lifeline and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Trident LifelineTLL | ₹319 Cr | — | — | — | 22.0% | — | — | -10.0% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Trident Lifeline
BSE: TLL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Trident Lifeline's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Trident Lifeline Limited is a pharmaceutical company based in Surat that focuses on the marketing and distribution of a diverse range of pharmaceutical formulations. The company operates as a merchant exporter and domestic supplier, providing products across therapeutic segments such as anti-bacterial, anti-fungal, and cardiovascular drugs.
Business Model
The company employs a lean asset-light contract manufacturing model, outsourcing production while focusing on supply chain management and distribution. It generates revenue through the sale of pharmaceutical products in both domestic Indian markets and international regions including Africa, South East Asia, and Latin America.
- Listing Platform:BSE SME
- Listing Year:2022
Management Commentary
Management is prioritising the expansion of the company's global footprint through strategic product registrations and the strengthening of its distribution network.
Growth Outlook
Growth is expected to be driven by the continued scaling of distribution capabilities and the acquisition of new international product registrations. The company aims to leverage its lean operating structure to penetrate further into emerging pharmaceutical markets.
Key Risks
- Regulatory Risk. The company is subject to stringent pharmaceutical regulations and quality standards in both domestic and international markets, which could impact product approvals.
- Dependency on Contract Manufacturers. As an asset-light entity, the company relies on third-party manufacturers, making it vulnerable to supply chain disruptions or quality control issues at partner facilities.
- Currency Fluctuation. Significant exposure to international markets in Africa, South East Asia, and Latin America exposes the company to risks associated with foreign exchange volatility.
- Competitive Market. The pharmaceutical distribution sector is highly fragmented and competitive, which may exert pressure on profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Trident Lifeline and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026